secwatch.observer — SEC 8-K summary
======================================

Issuer:     SERA PROGNOSTICS, INC. (SERA)
CIK:        0001534969
Form:       8-K
Filed at:   2025-01-31T23:59:59+00:00
Accession:  0001193125-25-018170
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sera Prognostics PRIME study meets both co-primary endpoints; cash $68.2M
-------------------------------------------------------------------------

- Cash, cash equivalents, and marketable securities were approximately $68.2 million as of December 31, 2024 (preliminary).
- PRIME study met both co-primary endpoints: 25% reduction in neonatal morbidity (NMI) and 18% reduction in neonatal length of stay in mITT population.
- ITT analysis: 20% reduction in NMI, 8% reduction in neonatal stay, and 20% reduction in NICU admissions.
- PreTRM test classified 23.5% as higher risk; number needed to screen 3-4 to save one NICU day.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534969/000119312525018170/0001193125-25-018170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534969/000119312525018170/d844948d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-018170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer